Nuvigil and Attention deficit hyperactivity disorder - a phase IV clinical study of FDA data

Summary:

Attention deficit hyperactivity disorder is reported as a side effect among people who take Nuvigil (armodafinil), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Xyrem, and have Cataplexy.

The phase IV clinical study analyzes which people have Attention deficit hyperactivity disorder when taking Nuvigil. It is created by eHealthMe based on reports of 22,424 people who have side effects when taking Nuvigil from the FDA, and is updated regularly.

What is Nuvigil?

Nuvigil has active ingredients of armodafinil. It is often used in narcolepsy. eHealthMe is studying from 23,669 Nuvigil users. Check the latest studies of Nuvigil.

What is Attention deficit hyperactivity disorder?

Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 610 drugs and 1,393 conditions by eHealthMe. Check the latest studies of Attention deficit hyperactivity disorder.

On Jul, 15, 2026

22,424 people reported to have side effects when taking Nuvigil.
Among them, 60 people (0.27%) have Attention deficit hyperactivity disorder.

Could Nuvigil cause Attention deficit hyperactivity disorder?

Among these 60 people:

How long have people been on Nuvigil when they have Attention deficit hyperactivity disorder? *

What is the gender of people who have Attention deficit hyperactivity disorder when taking Nuvigil? *

female: 63.33 %
male: 36.67 %

What is the age of people who have Attention deficit hyperactivity disorder when taking Nuvigil? *

What are other drugs people take besides Nuvigil? *

What are other side effects people have besides Attention deficit hyperactivity disorder? *

Stress And Anxiety: 14 people, 23.33%
Dizziness: 11 people, 18.33%
Pain: 11 people, 18.33%
Nausea (feeling of having an urge to vomit): 9 people, 15.00%
Depression: 8 people, 13.33%
Suicidal Ideation: 8 people, 13.33%
Weight Decreased: 7 people, 11.67%
Therapeutic Response Unexpected: 7 people, 11.67%
Drug Ineffective: 7 people, 11.67%
Fall: 7 people, 11.67%

What are the existing conditions these people have? *

Cataplexy (loss of muscle tone accompanied by full conscious awareness): 35 people, 58.33%
Depression: 5 people, 8.33%
Stress And Anxiety: 4 people, 6.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 5.00%
Irritable Bowel Syndrome: 2 people, 3.33%
Anaemia (lack of blood): 2 people, 3.33%
Diabetes: 2 people, 3.33%
Sinusitis (inflammation of sinus): 2 people, 3.33%
Acne Cystic (skin problems that cause pimples): 2 people, 3.33%
Neuralgia (pain in one or more nerves): 2 people, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Nuvigil and have Attention deficit hyperactivity disorder?

- Check whether Attention deficit hyperactivity disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nuvigil:

Nuvigil (23,669 reports)

Attention deficit hyperactivity disorder treatments and more:

Attention deficit hyperactivity disorder (120,336 reports)

How severe was Attention deficit hyperactivity disorder and when was it recovered:

Attention deficit hyperactivity disorder in Nuvigil

Expand to all the drugs that have ingredients of armodafinil:

Attention deficit hyperactivity disorder and drugs with ingredients of armodafinil (74 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Nuvigil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (610 drugs)

Browse all the conditions that are associated with Attention deficit hyperactivity disorder:

Attention deficit hyperactivity disorder (1,393 conditions)

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on armodafinil (the active ingredients of Nuvigil) and Nuvigil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.